Weekly News

Johnson & Johnson's Pharma Business Fuels Sales Growth

July 17,2018 17:18

J&J shares surged 4% to $128.65 in midday trading after the earnings report, though the stock is still down 7.9% year to date on investors' concerns about slower growth in other parts of J&J's diversified business, including consumer products. Global ...

Strong sales of Johnson & Johnson’s cancer drugs and other medicines helped boost the company’s revenue and earnings for the latest quarter, but the health-products giant’s U.S. consumer business continued to struggle.
Sales in the pharmaceuticals unit rose 19.9% globally, the largest increase among J&J segments. Cancer-drug sales rose 42.2%, helped by big gains for the Zytiga prostate-cancer drug and Darzalex, a blood-cancer treatment.

baby powder,earnings,earnings outlook,j&,j,johnson &, johnson,pharmaceuticals,profit,sales,talcum powder,Johnson &, Johnson,JNJ,Joe Wolk,Alex Gorsky,financial performance,sales figures,corporate,industrial news,cancer,political,general news,health,medical conditions,cancer drugs,health care,life sciences,specialized drugs,medications

Share this article

Related videos

How Big Oil Conquered the World
How Big Oil Conquered the World
Iowa Press Debate: U.S. Senate Republican Primary
Iowa Press Debate: U.S. Senate Republican Primary